Association between Expression of Osteopontin and Chinese Population with Hepatocellular Carcinoma and Its Clinical Pathological Characteristics: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 XUYing-yi ¹ , ZHANGYa-ya ¹ , LUWei-feng ² ,  CHENYu-qiang ¹

1. Department of Oncology, Chenggong Hospital Affiliated to Xiamen University and No. 174 Hospital of PLA, Xiamen 361003, China;
2. Department of Vascular Surgery, Zhongshan Hospital, Xiamen University, Xiamen 361004, China;

Corresponding?author：

CHENYu-qiang, Email: chenyq707@163.com

Keywords：

Osteopontin; Expression; Hepatocellular carcinoma; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20140228

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the association between expression of osteopontin (OPN) and Chinese population with hepatocellular carcinoma (HCC) and its clinical pathological characteristics. Methods Such databases including CBM, CNKI, VIP and WanFang Data were searched from inception to July 2014, for studies about the association between expression of OPN and Chinese population with HCC and its clinical pathological characteristics. Two reviewers independently screened literature according to the exclusion and inclusion criteria, extracted data, and assessed methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 case-control studies (involving 723 HCC cases and 102 controls) were included. The results of meta-analysis showed that:OPN expression was higher in HCC group than normal control group (OR=10.25, 95%CI 6.13 to17.14); and higher in imperfect capsular infiltration group than perfect capsular infiltration group (OR=2.71, 95%CI 1.58 to 4.64). However, no significant difference was found in OPN expression between isolated tumour group and multiple tumours group (OR=0.95, 95%CI 0.56 to 1.62); between high differentiation group and low differentiation group (OR=0.60, 95%CI 0.36 to 1.01); and between clinical stages I-Ⅱ group and clinical stages Ⅲ-IV group (OR=0.93, 95%CI 0.53 to 1.63). Conclusion Current evidence shows that OPN may take part in the whole course (occurrence and advance) of HCC in Chinese population, but the problem whether it can be used as a factor to evaluate prognosis needs to be further studied.

Citation： XUYing-yi, ZHANGYa-ya, LUWei-feng, CHENYu-qiang. Association between Expression of Osteopontin and Chinese Population with Hepatocellular Carcinoma and Its Clinical Pathological Characteristics: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(12): 1418-1423. doi: 10.7507/1672-2531.20140228 Copy

1.	李征, 米登海, 楊克虎, 等.介入化療栓塞術聯合熱療治療原發性肝癌的Meta分析.中國循證醫學雜志, 2012, 12(6):672-678.
2.	沈蔚, 張家敏, 毛根軍, 等. OPN和MMP-2在肝癌的表達及臨床意義.實用腫瘤學雜志, 2008, 22(5):437-438.
3.	林帆, 李瑜元, 溫敏杰, 等.骨橋蛋白在肝細胞癌中的表達及其臨床病理意義.中華生物醫學工程雜志, 2009, 15(3):216-219.
4.	劉兵團, 張國新, 郝波, 等.骨橋蛋白在肝癌患者外周血和癌組織中的含量及其臨床意義.蘇州醫藥, 2007, 33(11):1081-1083.
5.	姜偉棟, 印芳穎, 張明威, 等.原發性肝癌組織中骨橋蛋白與MMP-2的表達及臨床意義.臨床肝膽病雜志, 2006, 22(6):439-441.
6.	張嵐, 李海玉, 殷曉璐, 等.骨橋蛋白下游信號分子在肝細胞癌中的表達.中華肝臟病雜志, 2011, 19(1):48-51.
7.	劉秀峰, 施瑞華, 張國新, 等. OPN和Syndecan-1在原發性肝癌中的表達及與臨床病理參數之間的相關性.世界華人消化雜志, 2007, 15(16):1800-1805.
8.	郜玉峰, 李旭, 謝琴秀, 等.骨橋蛋白和CD44v6在肝癌中的表達及意義.中華肝臟病雜志, 2005, 13(3):227-228.
9.	曾文, 劉青光, 姚英民.骨橋蛋白、甲胎蛋白表達與原發性肝癌的關系.中國普通外科雜志, 2007, 16(8):806-808.
10.	萬幼峰, 許英藝, 張雅雅, 等.肝癌組織中骨橋蛋白的表達與臨床病理因素的相關性研究.臨床軍醫雜志, 2012, 40(2):376-378.
11.	陸健, 卞建民, 時開網, 等.肝細胞癌組織中骨橋蛋白的表達及其與血管生成的關系.山東醫藥, 2006, 46(9):3-5.
12.	Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomized studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
13.	李澤文, 周潔, 何源萍, 等.喉癌組織中Survivin表達及其臨床意義的Meta分析.中國循證醫學雜志, 2013, 13(10):1200-1208.
14.	Wai PY, Kuo PC. The ro1e of Osteopontin in tumor metastasis. J Surg Res, 2004, 121(2):228-241.
15.	Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1):184-190.
16.	Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis associated protein osteopontin in human breast cancer. Cancer Res, 2002, 62(12):3417-3427.
17.	高偉, 司雁菱, 吳瑜.骨橋蛋白、PTEN蛋白和C-met跨膜蛋白在肝細胞癌中的表達及意義.中國臨床醫學, 2009, 16(3):377-379.
18.	武金才, 孫冰生, 劉道永, 等.比較基因組雜交芯片技術對肝癌組織中骨橋蛋白不同表達腫瘤細胞基因組的研究.中華肝膽外科雜志, 2008, 14(12):854-857.
19.	魏少峰, 郜玉峰, 李旭, 等.骨橋蛋白和P21在原發性肝癌中的表達及其臨床意義.實用肝臟病雜志, 2005, 8(2):73-76.
20.	陳發龍, 陳軍, 曾麗.骨橋蛋白與MMP-9在肝細胞癌中的表達及其臨床意義.中國腫瘤臨床, 2007, 34(20):1160-1163.
21.	陳榮新, 葉勝龍, 李濤, 等.骨橋蛋白在不同轉移潛能肝癌細胞系及肝癌組織中表達意義.中華肝膽外科雜志, 2009, 15(4):279-282.

1. 李征, 米登海, 楊克虎, 等.介入化療栓塞術聯合熱療治療原發性肝癌的Meta分析.中國循證醫學雜志, 2012, 12(6):672-678.
2. 沈蔚, 張家敏, 毛根軍, 等. OPN和MMP-2在肝癌的表達及臨床意義.實用腫瘤學雜志, 2008, 22(5):437-438.
3. 林帆, 李瑜元, 溫敏杰, 等.骨橋蛋白在肝細胞癌中的表達及其臨床病理意義.中華生物醫學工程雜志, 2009, 15(3):216-219.
4. 劉兵團, 張國新, 郝波, 等.骨橋蛋白在肝癌患者外周血和癌組織中的含量及其臨床意義.蘇州醫藥, 2007, 33(11):1081-1083.
5. 姜偉棟, 印芳穎, 張明威, 等.原發性肝癌組織中骨橋蛋白與MMP-2的表達及臨床意義.臨床肝膽病雜志, 2006, 22(6):439-441.
6. 張嵐, 李海玉, 殷曉璐, 等.骨橋蛋白下游信號分子在肝細胞癌中的表達.中華肝臟病雜志, 2011, 19(1):48-51.
7. 劉秀峰, 施瑞華, 張國新, 等. OPN和Syndecan-1在原發性肝癌中的表達及與臨床病理參數之間的相關性.世界華人消化雜志, 2007, 15(16):1800-1805.
8. 郜玉峰, 李旭, 謝琴秀, 等.骨橋蛋白和CD44v6在肝癌中的表達及意義.中華肝臟病雜志, 2005, 13(3):227-228.
9. 曾文, 劉青光, 姚英民.骨橋蛋白、甲胎蛋白表達與原發性肝癌的關系.中國普通外科雜志, 2007, 16(8):806-808.
10. 萬幼峰, 許英藝, 張雅雅, 等.肝癌組織中骨橋蛋白的表達與臨床病理因素的相關性研究.臨床軍醫雜志, 2012, 40(2):376-378.
11. 陸健, 卞建民, 時開網, 等.肝細胞癌組織中骨橋蛋白的表達及其與血管生成的關系.山東醫藥, 2006, 46(9):3-5.
12. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of nonrandomized studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
13. 李澤文, 周潔, 何源萍, 等.喉癌組織中Survivin表達及其臨床意義的Meta分析.中國循證醫學雜志, 2013, 13(10):1200-1208.
14. Wai PY, Kuo PC. The ro1e of Osteopontin in tumor metastasis. J Surg Res, 2004, 121(2):228-241.
15. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1):184-190.
16. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis associated protein osteopontin in human breast cancer. Cancer Res, 2002, 62(12):3417-3427.
17. 高偉, 司雁菱, 吳瑜.骨橋蛋白、PTEN蛋白和C-met跨膜蛋白在肝細胞癌中的表達及意義.中國臨床醫學, 2009, 16(3):377-379.
18. 武金才, 孫冰生, 劉道永, 等.比較基因組雜交芯片技術對肝癌組織中骨橋蛋白不同表達腫瘤細胞基因組的研究.中華肝膽外科雜志, 2008, 14(12):854-857.
19. 魏少峰, 郜玉峰, 李旭, 等.骨橋蛋白和P21在原發性肝癌中的表達及其臨床意義.實用肝臟病雜志, 2005, 8(2):73-76.
20. 陳發龍, 陳軍, 曾麗.骨橋蛋白與MMP-9在肝細胞癌中的表達及其臨床意義.中國腫瘤臨床, 2007, 34(20):1160-1163.
21. 陳榮新, 葉勝龍, 李濤, 等.骨橋蛋白在不同轉移潛能肝癌細胞系及肝癌組織中表達意義.中華肝膽外科雜志, 2009, 15(4):279-282.

Chinese Journal of Evidence-Based Medicine

Association between Expression of Osteopontin and Chinese Population with Hepatocellular Carcinoma and Its Clinical Pathological Characteristics: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content